Suppr超能文献

微小 RNA 与丙型肝炎病毒:miR-122 一统天下的局面或将结束。

MicroRNAs and hepatitis C virus: toward the end of miR-122 supremacy.

机构信息

EA4294 Unité de Virologie Clinique et Fondamentale, Université de Picardie Jules Verne, UFR de Médecine et de Pharmacie, 3 rue des Louvels, 80036, Amiens Cedex, France.

出版信息

Virol J. 2012 Jun 12;9:109. doi: 10.1186/1743-422X-9-109.

Abstract

The most common etiologic agents causing chronic hepatitis are hepatitis C and B viruses (HCV and HBV, respectively). Chronic infection caused by HCV is considered one of the major causative agents of liver cirrhosis and hepatocellular carcinoma worldwide. In combination with the increasing rate of new HCV infections, the lack of a current vaccine and/or an effective treatment for this virus continues to be a major public health challenge. The development of new treatments requires a better understanding of the virus and its interaction with the different components of the host cell. MicroRNAs (miRNAs) are small non-coding RNAs functioning as negative regulators of gene expression and represent an interesting lead to study HCV infection and to identify new therapeutic targets. Until now, microRNA-122 (miR-122) and its implication in HCV infection have been the focus of different published studies and reviews. Here we will review recent advances in the relationship between HCV infection and miRNAs, showing that some of them emerge in publications as challengers against the supremacy of miR-122.

摘要

引起慢性肝炎的最常见病原体是丙型肝炎病毒和乙型肝炎病毒(分别为 HCV 和 HBV)。由 HCV 引起的慢性感染被认为是全球肝硬化和肝细胞癌的主要病因之一。随着新 HCV 感染率的增加,目前尚无针对该病毒的疫苗和/或有效治疗方法,这仍然是一个主要的公共卫生挑战。新疗法的开发需要更好地了解病毒及其与宿主细胞不同成分的相互作用。微小 RNA(miRNA)是作为基因表达负调节剂的小非编码 RNA,是研究 HCV 感染和确定新治疗靶点的一个有趣线索。到目前为止,miR-122(miR-122)及其在 HCV 感染中的作用一直是不同已发表研究和综述的重点。在这里,我们将回顾 HCV 感染与 miRNA 之间关系的最新进展,表明其中一些 miRNA 在出版物中崭露头角,挑战 miR-122 的至高无上地位。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6c6/3489824/0f0a9f8319ba/1743-422X-9-109-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验